Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
| Autor: | João Abrão, Jaime Eduardo Cecílio Hallak, Mara R. C. Guimarães, João Paulo Machado-de-Sousa, Tiago M Guimarães |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Nausea RC435-571 Pilot Projects Placebo 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine medicine Humans Ketamine glutamatergic system Adverse effect Psychiatry Depressive Disorder Major nitrous oxide major depressive disorder business.industry medicine.disease equipment and supplies NMDA receptor Antidepressive Agents 030227 psychiatry Clinical trial Psychiatry and Mental health Treatment Outcome Vomiting Antidepressant Major depressive disorder Original Article medicine.symptom business Brazil 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Brazilian Journal of Psychiatry v.43 n.5 2021 Brazilian Journal of Psychiatry (São Paulo. 1999. Online) Associação Brasileira de Psiquiatria (ABP) instacron:ABP Brazilian Journal of Psychiatry, Volume: 43, Issue: 5, Pages: 484-493, Published: 15 FEB 2021 Brazilian Journal of Psychiatry, Vol 43, Iss 5, Pp 484-493 (2021) Brazilian Journal of Psychiatry |
| Popis: | Objective: Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O. Methods: This double blind, placebo-controlled randomized parallel pilot trial was conducted from June 2016 to June 2018 at the Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Twenty-three subjects with MDD (aged 18 to 65, on antidepressants, with a score > 17 on the 17-item-Hamilton Depression Rating Scale [HAM-D17]) received 50% N2O (n=12; 37.17±13.59 years) or placebo (100% oxygen) (n=11; 37.18±12.77 years) for 60 minutes twice a week for 4 weeks. The primary outcome was changes in HAM-D17 from baseline to week 4. Results: Depressive symptoms improved significantly in the N2O group (N2O: from 22.58±3.83 to 5.92±4.08; placebo: from 22.44±3.54 to 12.89±5.39, p < 0.005). A total of 91.7% and 75% of the N2O group subjects achieved response (≥ 50% reduction in HAM-D17 score) and remission (HAM-D17 < 7), respectively. The predominant adverse effects of N2O treatment were nausea, vomiting, and headache. Conclusion: N2O treatment led to a statistically significant reduction in HAM-D17 scores compared to placebo. Clinical trial registration: Brazilian Register of Clinical Trials, RBR-5rz5ch |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|